Regeneron news and events in 2026
Regeneron is a biopharmaceutical organization that invents, develops, and commercializes medicines intended for individuals with serious diseases. The organization focuses its scientific efforts on several therapeutic areas, including metabolic diseases, ophthalmology, and rare diseases.
Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn
Get Regeneron's live signals in Claude or ChatGPT, or by API
What changed at Regeneron this week? Use Autobound signals for regeneron.com.- Dated updates
- 94
- Last event
- Oct 30, 2026
- Open rolesSnapshot Nov 3, 2026
- 156
- Latest SEC filing
- Oct 30, 2026
Source: Autobound Signal API · 94 signals tracked for Regeneron · updated
Overview
Regeneron by topic
110-K filing
156open roles
52+signals
37 in the last 90 days
- Glassdoor15+
- Website changes15+
- Patents12
- LinkedIn4
- and 3 more sources
Latest events
Latest Regeneron events
Showing 10 of 31 events. The Signal API returns all of them.
Get them with one API call- RevenueRegeneron Q3 Revenue Rises 36% to $5.12 BillionRegeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year.
- PartnershipRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessWith Biomedical Advanced Research and Development Authority
- Office expansionRegeneron strengthens its presence in Spain with a new headquarters and highlights the strategic role of MadridRegeneron inaugurated its new corporate headquarters in Madrid, Spain.
- InvestmentREGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing PledgeRegeneron committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.
- New customerSanofi expands its partnership with Regeneron in an $8 billion dealRegeneron will receive $1 billion upon signing and up to an additional $7 billion in future milestone payments from Sanofi as part of an expanded partnership.
- In development
- EarningsRegeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026Regeneron Pharmaceuticals will report its third quarter 2026 financial and operating results on October 30, 2026.
- In developmentParoxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market GrowthRegeneron Pharmaceuticals is developing Pozelimab + Cemdisiran, a potential therapy for paroxysmal nocturnal hemoglobinuria (PNH).
- LaunchRegeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOPRegeneron Pharmaceuticals received FDA approval for its drug Pasatru (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva (FOP).
- IntegrationVeeva Vault CRM Selected by RegeneronWith Veeva Systems
Showing 10 of 31 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Regeneron with the Signal API
One POST /v1/companies/enrich call with regeneron.com returns every signal type for Regeneron, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Regeneron
Regeneron questions
What is the latest news on Regeneron?
What is going on with Regeneron?
What else does Autobound track for Regeneron?
Is Regeneron hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .